SPRY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's beginner level, long-term strategy, and available capital, SPRY is not a strong buy at this moment. While the stock has potential due to its innovative product and positive analyst ratings, the recent financial performance and lack of strong trading signals suggest holding off for now.
The MACD is positive and expanding, indicating a slight bullish momentum. RSI is neutral at 56.471, and moving averages are converging, showing no clear trend. The stock is currently trading near its pivot level of 8.146, with support at 7.837 and resistance at 8.456.
Hedge funds are significantly increasing their positions, with a 326% increase in buying activity last quarter.
Analysts have initiated coverage with an Outperform rating and a $25 price target, citing the disruptive potential of the company's needle-free epinephrine product.
The company's financial performance in Q4 2025 was poor, with revenue, net income, and EPS all showing significant YoY declines.
No recent news or congress trading data to provide additional positive sentiment.
In Q4 2025, revenue dropped by 67.56% YoY to $28.09M, net income fell by 182.76% YoY to -$41.32M, and EPS declined by 200% YoY to -0.42. Gross margin also decreased by 21.12% YoY to 78.09%.
Northland initiated coverage with an Outperform rating and a $25 price target, highlighting the potential of the company's innovative product to disrupt the market and drive adoption.
